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Abstract 
Aims: To evaluate the risk of severe hypoglycemia for people with Type 1 diabetes (T1D) when 
exposed to insulin regimens including human insulin only or insulin analogues.  
Methods: A total of 19,896 people with T1D were extracted from the Danish National Patient 
Register. 6,379 T1D people experiencing one of more severe hypoglycemic episodes (total of 
17,242 episodes) were matched 1:1 with T1D people without severe hypoglycemia. A logistic 
regression model with last insulin regimen used as exposure was constructed to analyse the 
effect on severe hypoglycemia.   
Results: People on a basal-bolus regimen with insulin analogues had a reduced risk of severe 
hypoglycemia of 39% (OR: 0.61, 95% CI: 0.54-0.68) compared to people on a basal-bolus 
human insulin only regimen. Furthermore, people on a pre-mixed regimen containing an 
insulin analogue had a 58% (OR: 0.42, 95% CI: 0.36-0.49) reduced risk of severe hypoglycemia 
compared to people on a pre-mixed human insulin only. 
Conclusions: This study indicates that use of a basal-bolus insulin regimen with an insulin 
analogue is safer with respect to severe hypoglycemia in people with T1D than the use of a 
basal-bolus human insulin only regimen.  
 
1: What is already known about this subject:  
- Meta-analysis of randomised controlled trials indicate that insulin analogues reduce 
the risk of devastating severe hypoglycemic episodes compared to human insulin.  
- Real-world evidence confirming these results is very sparse but necessary because 
population selections in randomized controlled trials are typically unnatural leading to 
less generalisable results. 
2: What this study adds:  
- From investigation of more than 6,000 people suffering from severe hypoglycemic 
episodes, insulin analogues in a treatment regimen do reduce the risk of severe 
hypoglycemia with up to 30%. 
- These real-world results suggest that clinicians should consider treating their patients 
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Introduction 
Late-complications in diabetes mellitus is a major cause of morbidity and premature 
mortality[1]. The late-diabetic complications include retinopathy, nephropathy, neuropathy 
and macrovascular diseases and are a consequence of the abnormal hyperglycemic stage[2]. 
To obtain euglycemia, tight glycemic control is thus necessary, and major studies have shown 
that intensive insulin therapy aiming at near-normal glucose levels reduces risk of both micro- 
and macrovascular late-complications[3,4]. However, the reduction in glucose levels 
increases the risk of severe hypoglycemia[5]. Severe hypoglycemia is a major challenge for 
people with diabetes and reduces quality of life[3,6]. Furthermore, severe hypoglycemia is 
associated with the risk of major microvascular events[5] and has been associated with the 
dead-in-bed syndrome [7,8]. Severe hypoglycemic episodes lead to therapeutic incompliance 
and expensive hospital-admissions confirmed by a study where 7% of the severe episodes for 
people with type 1 and 2 diabetes led to hospital admissions > 24 hours[9]. Lastly, the 
recurrent hypoglycemic episodes impair the hypoglycemic counterregulatory hormonal 
response, which, in turn increases the risk of subsequent episodes[10,11], i.e. a vicious circle. 
The risk factors for severe hypoglycemia include diabetes duration, hypoglycemia 
unawareness, loss of endogenous insulin secretion, inappropriate exogenous insulin use[12]. 
In older T1D people, the risk of severe hypoglycemia increases, which is linked to the risk 
factors of unawareness and glucose variability[13]. Human insulins have been the standard 
basal, basal-bolus and pre-mixed insulin treatment for insulin-dependent people with 
diabetes for many years, but recent clinical trials have paved the way for approval of a variety 
of insulin analogues with insulin lispro as the first analogue introduced to the US market in 
1996. The different properties of insulin analogues enable once daily administrations and 
better glycemic control including less severe hypoglycemic episodes[14–17]. One study[18] 
showed that an insulin analogue increases the risk of severe hypoglycemia, but confounding 
by indication could not be ruled out. Real-world evidence on change in frequency of severe 
hypoglycemia remains sparse. Real-world evidence is important to include in the evaluation 
of insulin analogues, because the results from the clinical trials might be biased due to 
unrealistic titration procedures and exclusion of people with recurrent hypoglycemia. Some 
real-world studies have showed that insulin analogues are associated with a lower risk of 
severe hypoglycemia compared to human insulins[14,19,20] with varying population under 
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investigation (T2D, T1D, T1D+T2D, respectively). Typically, the studies only compare basal 
regimens and single products although basal-bolus is the most widely used regimen[21].  
This study sought to evaluate the risk of severe hypoglycemia for people with T1D when 
exposed to basal, bolus, basal-bolus and pre-mixed insulin (mix insulin) regimens including 




This was an observational study, and ethics committee approval was according to local 
regulations thus not required. 
 
2.1 Study design 
The investigation was carried out using a case-control study of adults admitted to hospitals in 
Denmark from 1st of January 1996 to 31st of December 2017. The people enrolled in this study 
can be seen in Figure 1. Cases experienced hypoglycemic episodes leading to hospital 
admission and controls did not. Controls were matched to cases 1:1 by age and gender.  
People with T1D were identified using the International Classification of Diseases 10 (ICD-10) 
system and the Anatomical Therapeutical Chemical (ATC) classification system. T1D people 
(n=19,896) should have at least one DE10 (Type 1 diabetes mellitus) ICD-code and at least one 
A10A (insulins and analogues) ATC code and no A10B (blood glucose lowering drugs, excl. 
insulins) ATC code. 
 
2.2 Source of data 
Diagnosis of diabetes, hypoglycemia and concomitant illnesses were extracted from the 
Danish National Patient Register. The Danish National Patient Register was established in 
1977 and initially covered information on inpatient in somatic wards. Since then it has been 
expanded and now includes information on all patients in Danish hospitals. The validity of 
registrations are in general very high.[22–24] Insulin use and concomitant medications were 
extracted from the National Pharmacological Database by the Danish Medicines Agency. The 
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2.3 Endpoint and exposure 
The endpoint (outcome) in the study was hypoglycemia leading to hospital admission. In a 
study by Heller et al.[9] of people with type 1 and type 2 diabetes, only 19% of severe 
hypoglycemic episodes led to emergency room attendance/hospital admission (64 “Hospital 
or emergency room ≤ 24 h” and 36 “Hospital > 24 h” of 536 events), and the episodes 
investigated in this study are thus of high severity and from now on referred to as severe 
hypoglycemia. The episodes (nobs=17,242) were identified via the ICD-10 codes DE159 
(hypoglycemic coma, unspecified), DE160 (drug-induced hypoglycemia without coma), DE161 
(other hypoglycemia), DE161B (encephalopathy following hypoglycemic coma) and DE162 
(Hypoglycemia, unspecified). Only the last hypoglycemic episode experienced by each person 
was included in the investigation. The control people inherited this hypoglycemia date of their 
matched cases as a dummy date. Exposure was last insulin regimen used in the period from 
the hypoglycemia date/dummy date and 180 days prior. Insulin use was defined as 
prescriptions of insulin, and the 6 months interval was thus chosen to ensure that 
prescriptions exist. Only cases with the same regimen throughout the period were kept.  Both 
bolus, basal and pre-mixed insulins were categorised into being an analogue or not as seen in 
Table 1.  
The different insulin regimens can be seen in Table 2. “Mix insulin” is pre-mixed insulin 
containing only human insulin products whereas “Mix insulin analogue” is pre-mixed insulin 
with either one or two insulin analogues. Insulin dose was calculated as the sum of the units 
of dispensed insulin in the defined exposure period before the hypoglycemic episode/dummy 
date divided by the exposure period duration. 
 
2.4 Statistical analyses 
Descriptive statistics will be presented with mean and standard deviation (SD) or percentage 
of people. T-tests, Chi-square tests and Mann-Whitney U tests will be used to present 
statistical differences in person characteristics. Age and diabetes duration are calculated from 
date of birth and date of diagnosis, respectively, to hypoglycemia date/dummy date. Late-
diabetic complications is presented in the following categories: Nephropathy (ICD-10: DE102), 
retinopathy (ICD-10: DE103), neuropathy (ICD-10: DE104-5), multiple (ICD-10: DE107 or >1 of 
the mentioned complications) and other (ICD-10: DE106, DE108).  
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A logistic regression model was constructed to analyse the effect of the insulin regimens on 
severe hypoglycemia. The most widely used regimen “Basal insulin + bolus insulin” (cf. Table 
2) was used as reference for the other regimens. The model included use of glucocorticoids 
(ATC: H02AB), use of agents acting on the renin-angiotensin system (ATC: C09) use of beta 
blocking agents (ATC: C07), use of antiepileptics (ATC: N03AX12, N03AX16), use of 
antidepressants (ATC: N06AA), history of alcohol abuse (ICD-10: DF10, DZ721) and history of 
liver disease (ICD-10: DK70, DK71, DK74) as dichotomous covariates. These covariates are 
judged as potential confounders as they all affect the glucose metabolism and may be 
associated with insulin regimens. Furthermore, the model was adjusted for diabetes duration 
and late-diabetic complications. 
The descriptive and inferential analyses were conducted in SAS 9.4. The significance level was 
set at a p value of less than 0.05 for two-sided testing.  
 
Results 
Table 3 shows the person characteristics of the case-control. The control group has a lower 
diabetes duration and, therefore, in general less late-diabetic complications. Daily insulin use 
is slightly lower in the control group. Person characteristics for each insulin regimen can be 
seen in Table 4. 
The results of the logistic regression can be seen in Table 5. Using a regimen with an insulin 
analogue resulted in an almost 40% lower risk of severe hypoglycemia as can be seen in all 
three basal-bolus regimens. Furthermore, there is a risk-reduction for people on a bolus 
insulin analogue. On the other hand, using a mix human insulin only and a basal human insulin 
regimen seem to increase the risk of severe hypoglycemia compared to using a basal-bolus 
human insulin only regimen. A model with mix human insulin only as reference showed an 
odds ratio of 0.42 with 95% CI of 0.36 to 0.49 for people on a mix insulin analogue regimen. 
 
Discussion 
Findings from this study indicate that the risk of severe hypoglycemic episodes is up to 39% 
lower for people on a basal-bolus insulin analogue regimen compared to people on a basal-
bolus human insulin only regimen. Furthermore, people on a bolus insulin analogue regimen 
had a reduced risk of severe hypoglycemia. On the contrary, people on a mix human insulin 
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only regimen had a 2-fold increase in risk of severe hypoglycemia compared to people on a 
basal-bolus human only insulin regimen. 
A register study by Strandberg et al.[20] including both people with T1D and type 2 diabetes 
(T2D) showed a similar risk-reduction of 30% and 24% in severe hypoglycemia for the insulin 
analogues of insulin glargine and insulin detemir, respectively, compared to the human insulin 
NPH (neutral protamine Hagedorn). In another register study, Ou et al.[19] investigated basal 
insulin analogues vs. basal human insulins on diabetes-related complications in T1D. They 
found a risk-reduction of approximately 35% in severe hypoglycemia for people on a basal 
insulin analogue compared to people on a basal human insulin. In a cross-over trial of 159 
people with T1D suffering from recurrent severe hypoglycemia, Pedersen-Bjergaard et al.[17] 
found a comparable relative reduction in rate of severe hypoglycemia of 29% for people on a 
regimen with an insulin analogue compared to a human insulin. Other studies investigating 
the risk of hypoglycemia for people on insulin analogues compared to people on human 
insulins confirm the trend[25–27].   
In this study, a statistically significant risk-reduction for people on a bolus insulin analogue. 
From the characteristics of people in the different regimens, it is evident that people on a 
bolus insulin analogue are much younger with shorter diabetes duration and with less late-
diabetic complications. Although the model was adjusted for these confounders, other 
underlying comorbidities might be increasing the risk of severe hypoglycemia for people on a 
basal-bolus human insulin only regimen. Also, we observed that use of mix human insulin 
only, resulted in a pronounced increase in the risk of severe hypoglycemia compared to a 
basal-bolus human insulin only, and with mix human insulin only as reference, the risk of 
severe hypoglycemia was reduced by 58% for people on a mix insulin analogue, which is in 
line with a risk reduction in overall hypoglycemia for people on insulin glargine compared to 
mix human insulin in a study by Rys et al.[14] 
A major limitation in this study is the lack of HbA1c measurements. We have no indication of 
whether the lower risk of severe hypoglycemia comes at the expense of an increased HbA1c, 
and thereby a higher risk of earlier onset and accelerated progression of late-diabetic 
complications. However, the lower risk of severe hypoglycemia does not seem to be 
associated with a decreased daily insulin dose. Neither does the prevalence of late-diabetic 
complications within each regimen indicate a relation between reduced risk of severe 
hypoglycemia and less effective glucose control. Also, lack of hypoglycemia unawareness 
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status is a limitation, because higher hypoglycemia unawareness significantly increases the 
risk of severe hypoglycemia[28]. Another limitation is the use of ICD-10 codes for classification 
of T1D and T2D, identification of hypoglycemic episodes and for concomitant illnesses. The 
codes are entered manually by clinicians, and human errors will thus be present. Due to the 
fact that the Danish National Patient Register is known for registrations of high validity, the 
detrimental effect is deemed minimal though. Cases and controls could have been matched 
by year of diabetes diagnosis, but due to the resulting lower sample size, we chose only to 
adjust for diabetes duration. More than 10% of the population were users of a basal regimen, 
which is not typical for T1D, but a few patients were in Denmark formerly only treated with 
basal insulin. Furthermore, some people with T2D might have been classified erroneously as 
T1D in the register, and some people with a very low bolus insulin need, might not have had 
bolus insulin dispensed in the 180 days period. These are two clear limitations. Finally, a 
limitation is that only a small subset of the severe hypoglycemic episodes has been 
investigated. Severe hypoglycemic episodes that do not lead to hospitalization are equally 
important to avoid, and the results from this study might not be generalizable to these 
episodes.  
Use of an insulin analogue in a basal-bolus regimen compared to a basal-bolus human insulin 
only regimen is associated with a reduction in the risk of severe hypoglycemia in people with 
T1D. Moreover, use of a pre-mixed insulin regimen with an insulin analogue compared to a 
pre-mixed human insulin only regimen resulted in a lower risk of severe hypoglycemia. 
However, a limitation is that glucose control e.g. via HbA1c and hypoglycemia unawareness 
status is not available. These results do not reveal evidence on head-to-head investigations 
of different insulin analogues, which are also important, but they add to the sparse real-world 
evidence that insulin analogues are safer to use than human insulins with respect to severe 
hypoglycemia.  
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Table 1: Categoristation of insulin products into human basal/bolus/mix 
insulin or basal/bolus/mix insulin analogue. 
Insulin type Insulin product Group 
Bolus Actrapid® Bolus insulin 
Humulin® Regular Bolus insulin 
Insuman® Rapid Solostar® Bolus insulin 
Apidra® Bolus insulin 
analogue 
Fiasp® Bolus insulin 
analogue 
Humalog® Bolus insulin 
analogue 
NovoRapid® Bolus insulin 
analogue 
Basal Humulin® NPH (neutral 
protamine Hagedorn) 
Basal insulin 
Insulatard® Basal insulin 
Abasaglar KwikPen Basal insulin 
analogue 












Pre-mixed Mixtard® 30 Mix insulin 
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Table 2: Different insulin regimens based on categorisation 
of insulin products. Abbreviation is added and used for later 
reference in Table . 
Abbreviation Insulin regimen 
Ba0 Basal insulina 
Ba1 Basal insulin analogue 
Bo0 Bolus insulina 
Bo1 Bolus insulin analogue 
Ba0Bo0 Basal insulina + bolus insulina 
Ba1Bo0 Basal insulin analogue + bolus insulin 
Ba0Bo1 Basal insulina + bolus insulin analogue 
Ba1Bo1 Basal insulin analogue + bolus insulin 
analogue 
Mix0 Mix insulinb 
Mix1 Mix insulin analoguec 
a If ”analogue” is not mentioned then the insulin is human 
b Zero analogue components 
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Table 3: Person characteristics of cases and controls. 
 Cases Controls P 
n 6,379 6,379  
Age, mean (SD) 50 
(21) 
50 (21) - 
Sex    
Women (%) 44.3 44.3 - 
Men (%) 55.7 55.7 - 
Hypoglycaemic episodes 17,242 0 - 
Number of persons with 1 episode 3,199 0 - 
Number of persons with 2 
episodes 
1,303 0 - 
Number of persons with >2 
episode 
1,877 0 - 
Hypoglycemic episodes per 




    
Diabetes duration (yrs), mean (SD) 22 (9) 15 (10) <.0001 
Late-diabetic complications    
Nephropathy (%) 1.5 1.5 0.0003 
Retinopathy (%) 6.7 7.9 <.0001 
Neuropathy (%) 2.1 3.2 0.2855 
Multiple (%) 46.5 23.7 <.0001 
Other (%) 12.5 10.9 <.0001 
Daily insulin dose (IU), mean (SD) 94 
(57) 
91 (56) 0.0025 
Insulin Regimena    
Basal insulin (%) 8.1 11.8 <.0001 
Basal insulin analogue (%) 2.8 1.8 <.0001 
Bolus insulin (%) 2.9 2.7 0.0977 
Bolus insulin analogue (%) 7.7 8.4 <.0001 
Basal insulin + bolus insulin (%) 22.7 21.5 0.1179 
Basal insulin + bolus insulin 
analogue(%) 
7.6 9.7 <.0001 
Basal insulin analogue + bolus 
insulin (%) 
3.0 2.3 <.0001 
Basal insulin analogue + bolus 
insulin analogue (%) 
25.3 23.8 0.0085 
Mix insulin (%) 16.1 13.5 <.0001 
Mix insulin analogue (%) 3.9 4.4 0.9046 
Other covariatesa    
Glucocorticoids (%) 3.9 3.0 0.0026 
Renin-angiotensin agents (%) 42.1 34.8 <.0001 
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Beta blocking agents (%) 15.4 9.8 <.0001 
Antiepileptics (%) 3.7 1.5 <.0001 
Antidepressants (%) 3.4 2.1 <.0001 
History of alcohol abuse (%) 5.9 3.1 <.0001 
Previous liver disease (%) 0.2 0.5 0.0078 
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Table 4: Person characteristics for each insulin regimen including people experiencing severe 
hypoglycemia and people without. The percentages are of people within regimen. Please refer to 
Table  for explanation of insulin regimen abbreviations. 
 
 Insulin regimens 










n 1,268 298 356 1,024 2,820 1,105 335 3,134 1,887 531 
Hypoglycemic/dummy 
episodes 
3,431 677 1,172 1,908 10,465 2,997 840 6,233 5,564 1,248 





















Sex           
Women (%) 47.2 44.0 42.7 50.0 42.8 37.9 46.0 43.3 47.6 41.1 
Men (%) 52.8 56.0 57.3 50.0 57.2 62.1 54.0 56.7 52.4 58.9 







































Late-diabetic complications           
Nephropathy (%) 2.7 0.0 2.2 0.6 1.8 1.8 0.9 1.0 1.6 2.1 
Retinopathy (%) 5.0 5.4 8.1 7.1 10.0 7.0 8.7 8.4 3.8 5.5 
Neuropathy (%) 4.5 2.0 2.0 0.7 3.1 2.4 3.0 1.8 3.2 4.3 
Multiple (%) 30.4 59.1 42.7 22.9 34.6 26.5 52.5 36.8 37.9 40.9 
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Table 5: Logistic regression with episodes of hypoglycemia and episodes 
without as outcome and insulin regimens as exposure. The reference in 
the model was the most frequent regimen: Basal insulin + bolus insulin. 
Insulin regimen 







Basal insulin analogue 0.88 (0.66-1.16) 0.6899 
Bolus insulin 0.96 (0.75-1.23) 0.7002 





















Mix insulin analogue 0.87 (0.71-1.08) 0.5729 
The model was adjusted for age, sex, diabetes duration, daily insulin 
dose, late-diabetic complications, glucocorticoids, renin-angiotensin 
agents, beta blocking agents, antiepileptics, antidepressives, history of 
alcohol abuse and previous liver diseases. 
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Figure 1: Number of people in the case-control study. From the available people from the 
Danish National Patient Register, 19,896 were identified as having Type 1 diabetes (T1D). 
6,379 T1D people experiencing hypoglycemic episodes leading to hospital admission were 
matched 1:1 by age and gender with people without hypoglycemic episodes leading to 
hospital admission.  
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